Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Live attenuated prrsv, strain vp-046 bis
Laboratorios Hipra S.A.
QI09AD03
Live attenuated prrsv, strain vp-046 bis
10(3.5) - 10(5.5) cell culture infective dose 50/dose
Lyophilisate and solvent for suspension for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Pigs
porcine reproductive and respiratory syndrome (PRRS) virus
Immunological - Live Vaccine
Authorised
2013-03-01
Health Products Regulatory Authority 31 January 2022 CRN00C90R Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT UNISTRAIN PRRS lyophilisate and solvent for suspension for injection for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose contains: Freeze-dried powder: Active substance: Live attenuated Porcine reproductive and respiratory syndrome virus (PRRSV), strain VP-046 BIS ………………………………………...............................................………………....………………........ 10 3.5 – 10 5.5 CCID 50 (_cell culture infectious dose_) Solvent: Phosphate buffer solution. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. Lyophilisate: white to yellowish powder. Solvent: Homogeneous-clear solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Breeding females: For active immunisation of breeding females from farms affected with European PRRS virus to reduce reproductive disorders, incidence and duration of viraemia, transplacental virus transmission, virus tissue load and clinical signs in the offspring associated with infection with strains of PRRS virus. Under laboratory conditions, vaccination of females reduced the negative impact of PRRS virus infection on piglet performance (mortality and weight gain) within the first 28 days of life. Onset of immunity: 30 days after vaccination. Duration of immunity: 16 weeks after vaccination. Pigs from 4 weeks of age: For active immunisation of pigs from farms affected with European PRRS virus to reduce clinical signs associated with a PRRS virus infection, the incidence and duration of viraemia and the duration of virus shedding by infected animals. Under experimental conditions, it was demonstrated that vaccination reduces the virus tissue load in the lungs. Under field conditions, where a PRRSV infection occurred during the fattening period, a reduction Read the complete document